Nothing said here yet.
to join the conversation.
Oncolytics published data showing pelareorep’s potential to turn an inactive liver tumor microenvironment active and susceptible to immune therapy.
Oncolytics announced continued clinical and operational progress for the REO 033 program evaluating pelareorep in second-line RAS-mutant mCRC.
Oncolytics announced positive preclinical results evaluating pelareorep in combination with a pan-RAS inhibitor in a RAS-driven colorectal cancer model.
By David Bautz, PhD NASDAQ: ONCY READ THE FULL ONCY RESEARCH REPORT Business Update Alignment Reached with FDA on Potential Registrational Pathway in CRC On August 18, 2026, Oncolytics Biotech, Inc.
Oncolytics Biotech has received FDA feedback supporting a potential pivotal expansion of its REO 033 colorectal cancer trial.
FDA written feedback provides alignment on a potential pivotal Part B expansion of the ongoing REO 033 study Proposed pathway offers potential accelerated approval based on objective response rate and progression-free survival supporting full approval Pivotal expansion to follow initial clinical data from the ongoing randomized Part A SAN DIEGO, Aug.
Designation supports development in an estimated $1 billion market where there are no FDA-approved therapies for patients whose disease progresses following first-line standard of care therapy Third Fast Track designation in gastrointestinal cancers strengthens Oncolytics’ regulatory momentum and continues to advance the Company’s path toward registration SAN DIEGO, July 20, 2026 (GLOBE NEWSWIRE) -- Oncolytics Biotech® Inc.
By David Bautz, PhD NASDAQ: ONCY READ THE FULL ONCY RESEARCH REPORT Business Update Seeking Alignment on Turning REO 033 Into a Registration-Directed Trial On July 13, 2026, Oncolytics Biotech, Inc.